

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.
CIN: L24232MH2007PLC169354; Tel: +91-22-24981650; Fax: +91-22-24970127
E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



PART I (Rs. in lakhs)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2014

PARTICULARS	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
	31.12.2014	30.9.2014	31.12.2013	31.12.2014	31.12.2013	31.3.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	5,648	5,662	5,479	17,189	17,824	22,938
(b) Other Operating Income	172	89	201	338	435	595
Total Income from Operations (Net)	5,820	5,751	5,680	17,527	18,259	23,533
2. Expenses						
(a) Cost of Materials Consumed	1,429	1,743	1,514	4,698	5,239	6,581
(b) Purchases of Stock-in-Trade	598	759	507	1,873	1,573	1,943
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(90)	(361)	(85)	(218)	(977)	(849)
(d) Employee Benefits Expense	1,683	1,892	1,510	5,136	4,722	6,218
(e) Depreciation and Amortisation Expense (including prior period credit of Rs. 56 lakhs) [Refer Notes 5 and 6]	306	300	271	832	788	1,061
(f) Provision for Doubtful Debts and Advances (Net) [Refer Note 4]	(404)	9	681	(386)	717	689
(g) Other Expenses	1,991	2,121	1,841	5,877	6,057	7,805
Total Expenses	5,513	6,463	6,239	17,812	18,119	23,448
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	307	(712)	(559)	(285)	140	85
4. Other Income	48	35	49	115	218	258
5. Profit/(Loss) from Ordinary Activities before Finance Costs and Exceptional Items	355	(677)	(510)	(170)	358	343
6. Finance Costs	88	70	34	200	221	260
7. Profit/(Loss) from Ordinary Activities after Finance Costs but before Exceptional Items	267	(747)	(544)	(370)	137	83
8. Exceptional Items	-	-	-	-	6,426	6,414
9. Profit/(Loss) from Ordinary Activities before Tax	267	(747)	(544)	(370)	6,563	6,497
10. Tax Expense/(Credit) (including Deferred Tax)	14	(8)	(242)	-	1,172	1,157
11. Net Profit/(Loss) for the period	253	(739)	(302)	(370)	5,391	5,340
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						11,253
14. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):						
(a) Basic	1.53	(4.47)	(1.83)	(2.24)	32.60	32.29
(b) Diluted	1.53	(4.47)	(1.83)	(2.24)	32.60	32.29

PART II
SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2014

PARTICULARS	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year ended
	31.12.2014	30.9.2014	31.12.2013	31.12.2014	31.12.2013	31.3.2014
A PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of Shares	6,312,564	6,312,564	7,196,344	6,312,564	7,196,344	6,380,451
- Percentage of Shareholding	38.17	38.17	43.52	38.17	43.52	38.59
2. Promoters and Promoter Group Shareholding						
(a) Pledged/Encumbered						
- Number of Shares	-	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-	-	-
(b) Non-Encumbered						
- Number of Shares	10,223,541	10,223,541	9,338,897	10,223,541	9,338,897	10,154,790
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the Company)	61.83	61.83	56.48	61.83	56.48	61.41

PARTICULARS	3 months ended 31.12.2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	8
Disposed of during the quarter	8
Remaining unresolved during the quarter	-

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 23rd January, 2015.
- The results for the quarter ended 31st December, 2014 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Provision for Doubtful Debts and Advances (Net) for the quarter and nine months ended 31st December, 2014 includes credit of an amount of Rs. 414 lakhs recovered from a party towards which provision was created in the corresponding quarter of previous year. Accordingly, the provision has been reversed by the amount received.
- Pursuant to the enactment of the Companies Act, 2013, effective 1st April, 2014, the management has evaluated and reassessed the useful life of its fixed assets. Consequent to such change, the charge on account of depreciation for the quarter is higher by Rs. 9 lakhs and for nine months ended 31st December, 2014 is higher by Rs. 30 Lakhs. Further, fixed assets of Rs. 1 lakh having no residual life as at 1st April, 2014, have been recognised in the opening balance of General Reserve.
- Depreciation expense for the nine months ended 31st December, 2014 includes prior period credit of Rs. 56 lakhs representing impact of rectification in the classification and estimated useful life of certain fixed assets.
- Figures for the prior periods have been regrouped where necessary.

For **RPG Life Sciences Limited**
CT. Renganathan
Managing Director
Mumbai, 23rd January, 2015